The Gut–Kidney Axis in Chronic Kidney Diseases
Diagnostics · 25.12.2024 · 15 (1) · 21
DOI: 10.3390/diagnostics15010021 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 25.12.2024. Verfasst von Kenji Tsuji und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama Uni…. Die Arbeit wurde bisher 108-mal zitiert (Crossref) und nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Japanese Society for the Promotion of Science (JSPS)/Grant-in-Aid for Young Scientists, Japanese Society for the Promotion of Science (JSPS).
Abstract (Originalsprache)
The gut–kidney axis represents the complex interactions between the gut microbiota and kidney, which significantly impact the progression of chronic kidney disease (CKD) and overall patient health. In CKD patients, imbalances in the gut microbiota promote the production of uremic toxins, such as indoxyl sulfate and p-cresyl sulfate, which impair renal function and contribute to systemic inflammation. Mechanisms like endotoxemia, immune activation and oxidative stress worsen renal damage by activating pro-inflammatory and oxidative pathways. Insights into these mechanisms highlight the impact of gut-derived metabolites, bacterial translocation, and immune response changes on kidney health, suggesting new potential approaches for CKD treatment. Clinical applications, such as dietary interventions, prebiotics, probiotics and fecal microbiota transplantation, are promising in adjusting the gut microbiota to alleviate CKD symptoms and slow disease progression. Current research highlights the clinical relevance of the gut–kidney axis, but further study is essential to clarify these mechanisms’ diagnostic biomarkers and optimize therapeutic interventions. This review emphasizes the importance of an integrated approach to CKD management, focusing on the gut microbiota as a therapeutic target to limit kidney injury.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Okayama 700-8558, Japan.
- Department of Nephrology, Aoe Clinic, Okayama 700-8607, Japan.
- Department of Nursing Science, Faculty of Health and Welfare Science, Okayama Prefectural University, Okayama 719-1197, Japan.
ORCID-Profile: Kenji Tsuji, Jun Wada
Förderung
- the Japanese Society for the Promotion of Science (JSPS)/Grant-in-Aid for Young Scientists
- Japanese Society for the Promotion of Science (JSPS)
Zitieren
APA
Tsuji, K., Uchida, N., Nakanoh, H., Fukushima, K., Haraguchi, S., Kitamura, S., & Wada, J. (2024). The Gut–Kidney Axis in Chronic Kidney Diseases. Diagnostics, 15(1), 21. https://doi.org/10.3390/diagnostics15010021
Vancouver
Tsuji K, Uchida N, Nakanoh H, Fukushima K, Haraguchi S, Kitamura S, et al. The Gut–Kidney Axis in Chronic Kidney Diseases. Diagnostics. 2024;15(1):21. doi:10.3390/diagnostics15010021
BibTeX
@article{Tsuji2024,
author = {Tsuji, Kenji and Uchida, Naruhiko and Nakanoh, Hiroyuki and Fukushima, Kazuhiko and Haraguchi, Soichiro and Kitamura, Shinji and Wada, Jun},
title = {The Gut–Kidney Axis in Chronic Kidney Diseases},
journal = {Diagnostics},
year = {2024},
volume = {15},
number = {1},
pages = {21},
doi = {10.3390/diagnostics15010021}
}
EUVIMED